ClinicalTrials.gg
CompletedNCT03867227Updated Mar 29, 2023

Non-pharmacological Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation

An observational study in Atrial Fibrillation, sponsored by National Research Center for Preventive Medicine. Completed at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by National Research Center for Preventive Medicine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Atrial Fibrillation with a site in Russian Federation — 4 open to participants now, 5 under way, none of them phase 3. Atrial Fibrillation · Russian Federation.

Enrollment
18th of 26
300 · median 1,063
Started
2018
with 5 others
Observational
26 of 107
1 open now
Registered
84th of 107
by date
Lead sponsor
3 of 107
National Research Center for Preventive Medicine

Among the 107 studies in Atrial Fibrillation with a site in Russian Federation, this one is the 18th largest by enrollment of the 26 observational ones that give a count, is one of 6 that started in 2018, is one of 26 observational ones, and was the 84th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 107 studies in Atrial Fibrillation with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Atrial Fibrillation with a site in Russian Federation, or all of them as a file.
02

Study summary

Left atrial appendage (LAA) occlude devices are used for over ten years. According to current data efficiency and safety of this approach at least comparable with pharmacological prevention of stroke in patients with non-valvular atrial fibrillation.

However, to date, LAA occluder implantation is not recommended as an alternative for conservative therapy and reserved for patients with contraindications for oral anticoagulants only. In the same time, long-term follow-up of patients enrolled in clinical trials and data from registries showed that LAA occlude device implantation as an alternative to oral anticoagulation could reduce drug load, decrease complexity and cost of treatment and thus improve patients' quality of life, and potentially may reduce the risk of death. The aim of our study is to investigate the risk of all-cause death, stroke, and bleedings in patients with LAA occluder implanted as an alternative to anticoagulant therapy.

Three hundred patients with atrial fibrillation will undergo LAA occluder implantation. For LAA occluder sizing transesophageal echocardiography (TEE), CT and LAA angiography will be performed. The follow-up period will be 36 months. The incidence of all-cause death, stroke, bleeding BARC≥2, device-related complications and QOL will be investigated.

The patients will be followed in the clinic at three and six months, and then at 12, 24 and 36 months, the telephone calls for getting information about endpoints events will be done. Additional in clinic visits will be scheduled if the late complications will be suspected.

TEE will be performed at three and six months to check for device leak, displacement and thrombosis.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • left atrial appendage
  • LAA occluder
  • thromboembolic prophylaxis
  • atrial fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients >18 years old with atrial fibrillation and high risk for tromboembolic events

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with paroxysmal/persistent/permanent atrial fibrillation
  • CHA2DS2VASc score ≥2 for male and ≥3 for female
  • Without to anticoagulation therapy

Exclusion criteria

Exclusion Criteria:

  • LAA thrombosis
  • mechanical prosthetic heart valve
  • moderate or severe mitral valve stenosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (actual)
Patient registry
No

Interventions

  • Deviceleft atrial appendage occluder implantation

    all patients will get implantation of LAA occluder

06

What researchers measure

Primary outcomes

  1. Number of patients with Composite of death, stroke, clinically significant bleeding event (>_2 class according to BARC criteria), device leak, device displacement or device thrombosis with the first event for a given patient is taken into account

    a clinically significant bleeding event is \>_2 class according to Bleeding Academic Research Consortium (BARC) criteria bleeding

    Time frame: 36 months

Secondary outcomes

  1. device thrombosis during first 6 months

    device thrombosis detected by transesophageal echocardiography during first 6 months of follow-up

    Time frame: 6 months

  2. device dislocation

    number of patients who would have device dislocation

    Time frame: 36 months

  3. any bleed

    total number of patients who would have any bleeding event

    Time frame: 36 months

  4. bleeding BARC ≥2

    total number of patients who would have bleeding event with the grade BARC ≥2

    Time frame: 36 months

  5. device leak and displacement during first 6 months

    device leak detected by transesophageal echocardiography during first 6 months after implantation or device displacement during the same time period

    Time frame: 6 months

  6. any adverse events during 7 days after LAA occluder implantation

    any adverse events related to the device implantation during the first 7 days after implantation

    Time frame: 7 days

  7. change in QOL SF 36 between baseline and final visit

    change in quality of life (QOL) by Short Form (SF) 36 Health Survey between baseline and follow-up visits SF 36 is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health. 0-100 scale are using to access each domain. lower the score the more disability.

    Time frame: Assessed at baseline and 6-month follow-up visits

  8. the percent of patients in whom long -term anticoagulation therapy would add during follow-up

    number of patients who would require adding permanent anticoagulant therapy for any reason during follow-up

    Time frame: 36 months

07

Study locations

1 site
  • . National Research Center for Preventive Medicine of the Ministry of Health
    Moscow, 101990, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Dec 2021, 36 months.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 36 months is below that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2019
First posted
Mar 7, 2019
StartActual
Dec 1, 2018
Primary completionActual
Dec 1, 2021
CompletionActual
Dec 1, 2022
Last update
Mar 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03867227
Lead sponsor
National Research Center for Preventive Medicine
Collaborators
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation, National Research Center of Surgery, Russia, I.M. Sechenov First Moscow State Medical University, Medical and Rehabilitation center
Responsible party
Sponsor
First posted
Mar 7, 2019
Start date
Dec 1, 2018
Primary completion
Dec 1, 2021
Completion
Dec 1, 2022
Last update
Mar 29, 2023

Study contacts

Karapet Davtyan
principal investigator · National Research Center for Preventive Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion